PMID- 32667078 OWN - NLM STAT- MEDLINE DCOM- 20210322 LR - 20210322 IS - 1530-6860 (Electronic) IS - 0892-6638 (Linking) VI - 34 IP - 9 DP - 2020 Sep TI - Depletion of miR-21 in dendritic cells aggravates renal ischemia-reperfusion injury. PG - 11729-11740 LID - 10.1096/fj.201903222RR [doi] AB - Dendritic cells (DCs) play an important role in the pathophysiology of renal ischemia-reperfusion injury (IRI). The mechanisms underlying DCs phenotypic modulation and their function are not fully understood. In this study, we examined the effect of miR-21 on the phenotypic modulation of DCs in vitro and in vivo, and further investigated the impact of miR-21-overexpression DC or miR-21-deficient DC on renal IRI. We found that treatment with hypoxia/reoxygenation (H/R) suppressed miR-21 expression in bone marrow-derived dendritic cells (BMDCs), and significantly increased the percentage of mature DCs (CD11c(+) /MHC-II(+) /CD80(+) ). Using a selection of microRNA mimics, we successfully induced the upregulation of miR-21 in BMDCs, which induced immature DC phenotype and an anti-inflammatory DC response. However, deletion of miR-21 in BMDCs promoted maturation of DCs under H/R. Adoptive transfer of miR-21-overexpression BMDCs could alleviate renal IR-induced pro-inflammatory cytokines production and acute kidney injury (AKI). Mice with miR-21 deficiency in DCs subjected to renal IR showed more severe renal dysfunction and inflammatory response compared with wild-type mice. In addition, chemokine C receptor 7 (CCR7), a surface marker of mature DC, was a target gene of miR-21, and silencing of CCR7 in BMDCs led to reduced mature DCs under H/R. In conclusion, our findings highlight miR-21 as a key regulator of DCs subset phenotype and a potential therapeutic target in renal IRI. CI - (c) 2020 Federation of American Societies for Experimental Biology. FAU - Jia, Ping AU - Jia P AD - Division of Nephrology, Zhongshan Hospital, Fudan University, Shanghai, China. AD - Kidney and Blood Purification Laboratory of Shanghai, Shanghai, China. FAU - Pan, Tianyi AU - Pan T AD - Division of Nephrology, Zhongshan Hospital, Fudan University, Shanghai, China. AD - Shanghai Medical Association, Shanghai, China. FAU - Xu, Sujuan AU - Xu S AD - Division of Nephrology, Zhongshan Hospital, Fudan University, Shanghai, China. FAU - Fang, Yi AU - Fang Y AD - Division of Nephrology, Zhongshan Hospital, Fudan University, Shanghai, China. FAU - Song, Nana AU - Song N AD - Division of Nephrology, Zhongshan Hospital, Fudan University, Shanghai, China. FAU - Guo, Man AU - Guo M AD - Division of Nephrology, Zhongshan Hospital, Fudan University, Shanghai, China. FAU - Liang, Yiran AU - Liang Y AD - Division of Nephrology, Zhongshan Hospital, Fudan University, Shanghai, China. FAU - Xu, Xialian AU - Xu X AD - Division of Nephrology, Zhongshan Hospital, Fudan University, Shanghai, China. FAU - Ding, Xiaoqiang AU - Ding X AD - Division of Nephrology, Zhongshan Hospital, Fudan University, Shanghai, China. AD - Kidney and Blood Purification Laboratory of Shanghai, Shanghai, China. AD - Shanghai Medical Center of Kidney, Shanghai, China. AD - Kidney and Dialysis Institute of Shanghai, Shanghai, China. AD - Hemodialysis Quality Control Center of Shanghai, Shanghai, China. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20200715 PL - United States TA - FASEB J JT - FASEB journal : official publication of the Federation of American Societies for Experimental Biology JID - 8804484 RN - 0 (Ccr7 protein, mouse) RN - 0 (MIRN-21 microRNA, mouse) RN - 0 (MicroRNAs) RN - 0 (Receptors, CCR7) SB - IM MH - Acute Kidney Injury/genetics/metabolism MH - Animals MH - Cells, Cultured MH - Dendritic Cells/*metabolism MH - *Gene Expression Regulation MH - Kidney/*metabolism/pathology MH - Male MH - Mice, Inbred C57BL MH - Mice, Knockout MH - MicroRNAs/*genetics MH - Receptors, CCR7/genetics/metabolism MH - Reperfusion Injury/*genetics/metabolism OTO - NOTNLM OT - acute kidney injury OT - dendritic cell OT - inflammation OT - microRNAs EDAT- 2020/07/16 06:00 MHDA- 2021/03/23 06:00 CRDT- 2020/07/16 06:00 PHST- 2019/12/23 00:00 [received] PHST- 2020/06/17 00:00 [revised] PHST- 2020/06/18 00:00 [accepted] PHST- 2020/07/16 06:00 [pubmed] PHST- 2021/03/23 06:00 [medline] PHST- 2020/07/16 06:00 [entrez] AID - 10.1096/fj.201903222RR [doi] PST - ppublish SO - FASEB J. 2020 Sep;34(9):11729-11740. doi: 10.1096/fj.201903222RR. Epub 2020 Jul 15.